C
Clare Gilson
Researcher at University College London
Publications - 27
Citations - 2655
Clare Gilson is an academic researcher from University College London. The author has contributed to research in topics: Prostate cancer & Androgen deprivation therapy. The author has an hindex of 10, co-authored 22 publications receiving 1826 citations. Previous affiliations of Clare Gilson include Churchill Hospital & Guy's Hospital.
Papers
More filters
Journal ArticleDOI
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James,Johann S. de Bono,Melissa R. Spears,Noel W. Clarke,Malcolm David Mason,David P. Dearnaley,Alastair W. S. Ritchie,Claire Amos,Clare Gilson,Robert Jones,David Matheson,Robin Millman,Gerhardt Attard,Simon Chowdhury,William Cross,Silke Gillessen,Chris Parker,J. Martin Russell,Dominik Berthold,Chris Brawley,Fawzi Adab,San Aung,Alison Birtle,Jo Bowen,Susannah Brock,Prabir Chakraborti,C.L. Ferguson,Joanna Gale,Emma Gray,Mohan Hingorani,Peter Hoskin,Jason F. Lester,Zafar Malik,Fiona McKinna,Neil McPhail,Julian Money-Kyrle,Joe M. O'Sullivan,Omi Parikh,Andrew Protheroe,Angus Robinson,Narayanan Srihari,Carys Thomas,John Wagstaff,James D. Wylie,Anjali Zarkar,Mahesh K.B. Parmar,Matthew R. Sydes +46 more
TL;DR: Among men with locally advanced or metastatic prostate cancer, ADT plus abiraterone and prednisolone was associated with significantly higher rates of overall and failure‐free survival than ADT alone.
Journal ArticleDOI
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Chris Parker,Nicholas D. James,Christopher D. Brawley,Noel W. Clarke,Alex Hoyle,Adnan Ali,A.W.S. Ritchie,Gerhardt Attard,Simon Chowdhury,William Cross,David P. Dearnaley,Silke Gillessen,Silke Gillessen,Clare Gilson,Robert Jones,Ruth E Langley,Zafar Malik,Malcolm David Mason,David Matheson,Robin Millman,J. Martin Russell,George N. Thalmann,Claire Amos,Roberto Alonzi,Amit Bahl,Alison Birtle,O.S. Din,Hassan Douis,C. Eswar,Joanna Gale,Melissa Gannon,Sai Jonnada,S. Khaksar,Jason F. Lester,Joe M. O'Sullivan,Omi Parikh,Ian Pedley,Delia Pudney,D. Sheehan,Narayanan Srihari,Anna T.H. Tran,Mahesh K.B. Parmar,Matthew R. Sydes +42 more
TL;DR: Radiotherapy to the prostate did not improve overall survival for unselected patients with newly diagnosed metastatic prostate cancer, and the benefit would be greatest in patients with a low metastatic burden.
Journal ArticleDOI
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
Matthew R. Sydes,Melissa R. Spears,Malcolm David Mason,Noel W. Clarke,David P. Dearnaley,J.S. de Bono,Gerhardt Attard,Simon Chowdhury,William Cross,Silke Gillessen,Silke Gillessen,Zafar Malik,Robert Jones,Robert Jones,Chris Parker,Chris Parker,A.W.S. Ritchie,J. M. Russell,J. M. Russell,Robin Millman,David Matheson,Claire Amos,Clare Gilson,A. Birtle,Susannah Brock,L. Capaldi,Prabir Chakraborti,Ananya Choudhury,Ananya Choudhury,L. Evans,Daniel Ford,Joanna Gale,Stephanie Gibbs,Duncan C. Gilbert,Robert Hughes,Duncan B. McLaren,Jason F. Lester,A. Nikapota,Joe M. O'Sullivan,Joe M. O'Sullivan,Omi Parikh,Clive Peedell,Andrew Protheroe,Sarah Rudman,R. Shaffer,D. Sheehan,Matthew S. Simms,Narayanan Srihari,Räto T. Strebel,Santhanam Sundar,Shaun Tolan,David Tsang,Mohini Varughese,John Wagstaff,Mahesh K.B. Parmar,Nicholas D. James +55 more
TL;DR: This direct, randomised comparative analysis of two new treatment standards for hormone-naïve prostate cancer showed no evidence of a difference in overall or prostate cancer-specific survival, nor in other important outcomes such as symptomatic skeletal events.
Journal ArticleDOI
Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
Alex Hoyle,Alex Hoyle,Adnan Ali,Nicholas D. James,Adrian Cook,Chris Parker,Johann S. de Bono,Gerhardt Attard,Simon Chowdhury,William Cross,David P. Dearnaley,Christopher D. Brawley,Clare Gilson,Fiona C. Ingleby,Silke Gillessen,Daniel M. Aebersold,Robert Jones,Robert Jones,David Matheson,Robin Millman,Malcolm David Mason,A.W.S. Ritchie,Martin J. Russell,Martin J. Russell,Hassan Douis,Mahesh K. B. Parmar,Matthew R. Sydes,Noel W. Clarke,Noel W. Clarke +28 more
TL;DR: Coadministration of abiraterone acetate and prednisolone with androgen deprivation therapy (ADT) is associated with prolonged overall survival and disease control, compared with ADT alone, in all men with metastatic disease starting hormone therapy for the first time.
Journal ArticleDOI
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
Malcolm David Mason,Noel W. Clarke,Nicholas D. James,David P. Dearnaley,Melissa R. Spears,Alastair W. S. Ritchie,Gerhardt Attard,William Cross,Robert Jones,Chris Parker,J. Martin Russell,George N. Thalmann,Francesca Schiavone,Estelle Cassoly,David Matheson,Robin Millman,Cyrill A. Rentsch,Jim Barber,Clare Gilson,Azman Ibrahim,John P Logue,Anna Lydon,A. Nikapota,Joe O’Sullivan,Emilio Porfiri,Andrew Protheroe,Narayanan Srihari,David Tsang,John Wagstaff,Jan Wallace,Catherine Walmsley,Mahesh K.B. Parmar,Matthew R. Sydes +32 more
TL;DR: These data show no overall evidence of improved survival with celecoxib (Cel), and preplanned subgroup analyses provide hypotheses for future studies.